drugset / Trial / NCT04175522
Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of IGIV 10% in patients with autoimmune encephalitis
Timeline
- Start
- 2019-11-20
- Primary completion
- 2020-06-11
- Completion
- 2020-06-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Immunoglobulin G | Protein / enzyme biologic | 400 mg/kg | Intravenous |